2.43
-5.45%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About FamiCord
Its shares trade on XETRA under the ticker V3V.DE. It has been listed since 27 March 2007. In the fiscal year to 31 December 2025, it reported revenue of €88.2m and a net loss of €6.3m. At that date it held total assets of €168.3m and shareholders' equity of €7.1m.
Vita 34 AG engages in the collection and storage of umbilical cord blood and stem cells. The company is headquartered in Leipzig, Sachsen. The company went IPO on 2007-03-27. The company operates through the Stem Cell Storage and the Biotechnology segment. The Stem Cell Storage segment collects, processes, and stores stem cells from umbilical cord blood and umbilical cord tissue, as well as develops cell therapy procedures. The Biotechnology segment develops biological processes for cell and tissue culture, as well as employs them in the optimization and multiplication of cells and plants. The company offers VitaPlusDonation that offers parents an alternative to the purely autologous storage or allogenic donation of umbilical cord blood; and Sibling Initiative program, which allows the storage free of charge of stem cells from the umbilical cord of a child whose brother or sister is seriously ill. The firm also provides prevention screening that helps to detect genetically related health risks and predispositions.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Providers & Services
- Listed since
- 27 Mar 2007
- Employees
- 117
- Website
- vita34.de ↗
Leadership
Pay as last reported
- Mr. Florian SchuhbauerChairman of the Supervisory Board, since 2020€45,593
- Mr. Jakub BaranChief Executive Officer, Member of the Management Board€436,973
- Mr. Peter GreinerDeputy Chairman of the Supervisory Board, since 2024€15,000
- Mr. Thomas PfaadtChief Financial Officer, Member of the Management Board€168,409
- Mr. Tomasz BaranMember of the Management Board, Chief Commercial Officer€307,755
- Mr. Frank KoehlerIndependent Member of the Supervisory Board, since 2017€30,000
- Mr. Konrad MiterskiIndependent Member of the Supervisory Board€22,542
- Dr. Ursula Schuetze-KreilkampIndependent Member of the Supervisory Board€20,000
- Mr. Paul OwsianowskiMember of the Supervisory Board€22,242
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Vita 34 AG is a leading company in the field of stem cell storage and regenerative medicine. It has a strong reputation and brand recognition, which gives it a competitive edge in the market.
- The company has a well-established customer base and a wide network of partner hospitals and clinics.
- Vita 34 AG possesses advanced technology and expertise in stem cell processing and cryopreservation, ensuring high-quality and reliable services.
Weaknesses
- One of the weaknesses of Vita 34 AG is its dependency on regulatory approvals and governmental policies, which can impact its operations and market potential.
- The company may face challenges related to customer education and awareness regarding the benefits and applications of stem cell storage.
- Vita 34 AG's geographical presence is mainly concentrated in specific regions, limiting its market reach and growth opportunities.
Opportunities
- The increasing acceptance of stem cell therapies and regenerative medicine presents an opportunity for Vita 34 AG to expand its services and customer base.
- Collaboration with research institutions and healthcare providers can lead to the development of new treatments and further advancements in the field, benefiting Vita 34 AG.
- International expansion and entering emerging markets with growing healthcare infrastructure can provide significant growth prospects for the company.
Threats
- Competition from other stem cell banks and companies offering similar services is a major threat to Vita 34 AG's market share and profitability.
- Changes in healthcare regulations and reimbursement policies can impact the demand for stem cell storage and affect the company's revenue streams.
- Ethical and legal concerns surrounding stem cell research and usage may impose restrictions and limitations on Vita 34 AG's operations.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.